What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally

Transaction summary

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($45.36); post-transaction worth based connected June 22, 2026 marketplace close.

Key questions

• What is the operation of Orbimed's ownership post-transaction?
  Following this transaction, each remaining 6,555,102 shares reported successful the filing are held indirectly done OrbiMed Genesis Master Fund, L.P. and OrbiMed Private Investments VII, LP.

• What proportionality of full holdings was impacted by this transaction?
  The merchantability represented 11.60% of Advisors Llc Orbimed's full indirect holdings anterior to the transaction, reflecting a meaningful simplification successful its aggregate ownership but not a afloat exit.

• How does existent trading discourse subordinate to the transaction price?
  The shares were sold astatine astir $45.36 per share, portion the banal closed astatine $45.96 connected June 22, 2026, and subsequently accrued to $50 arsenic of June 26, 2026, indicating a humble appreciation post-sale.

Company overview

* 1-year show calculated utilizing June 22nd, 2026 arsenic the notation date.

Company snapshot

• Enliven Therapeutics focuses connected the objective improvement of small-molecule kinase inhibitors, with its starring candidates ELVN-001 (for chronic myeloid leukemia) and ELVN-002 (for HER2-mutant cancers) some successful Phase 1 trials.

• The institution operates a research-driven model, aiming to make aboriginal gross by successfully developing, obtaining regulatory approval, and commercializing oregon licensing its oncology cause candidates.

• The superior people marketplace includes big patients with cancer, specifically those with chronic myeloid leukemia oregon HER2-driven malignancies, arsenic good arsenic the healthcare providers and institutions treating these populations.

Enliven Therapeutics, Inc. is simply a clinical-stage biotechnology institution headquartered successful Boulder, Colorado, with a absorption connected innovative small-molecule therapies for cancer. With a thin team, the institution channels resources into advancing its pipeline of kinase inhibitors for high-need oncology indications. Its strategy centers connected leveraging heavy technological expertise to code unmet aesculapian needs and make differentiated therapies successful the competitory crab therapeutics landscape.